Zealand Pharma: diabetes drug meets endpoints; shares rise
(CercleFinance.com) - Zealand Pharma said its anti-diabetic treatment has met its primary and key secondary endpoints in a late-stage pediatric trial, which has sent the Danish biotechnology company's shares up 6% in Tuesday afternoon trading.
The study's primary endpoint found that the median time to blood glucose recovery was 10 minutes for Zealand's dasiglucagon, which was superior to placebo (median: 30 minutes).
Invented and developed by Zealand, dasiglucagon is being developed in a ready-to-use self-injection rescue pens for fast treatment of severe hypoglycemia in people with diabetes.
Note that 42 children, aged 6 to 17, were enrolled in this Phase 3 trial.
Zealand has said that these positive results keep the company on track for submitting a new drug application to the US FDA in early 2020.
Its shares are currently up 6.5% in Copenhagen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.